A trombin a véralvadási kaszkád egyik kulcsenzime, amely mind pro-, mind antikoaguláns funkcióval rendelkezik. Központi szerepe folytán a trombin képződése a véralvadási folyamat egyik legfontosabb lépése, amely az úgynevezett trombingenerációs vizsgálattal jellemezhető. A trombingeneráció globális véralvadási teszt, amely átfogó képet ad a haemostasis állapotáról. Karakterisztikáját egyaránt befolyásolják a pro- és az antikoaguláns folyamatok, ezáltal alkalmas a fokozott trombóziskészség és a vérzékenység kimutatására is. Klinikai vizsgálatok igazolják a trombingeneráció fokozódását vénás és artériás trombózishajlam esetében. Segíthet az antikoaguláns terápia monitorozásában, faktorinhibitorokkal történő antikoaguláns kezelés esetében is. A trombingenerációs vizsgálatok eredményei hemofília esetén jól tükrözik a vérzés súlyosságát, és monitorozható a faktorkészítményekkel történő terápia. Információt adhat azokban az esetekben is, amikor a hemofíliás betegnél inhibitorok jelennek meg, és emiatt speciális kezelésre van szükség. A klinikai gyakorlatban történő alkalmazáshoz elengedhetetlen a módszer standardizálása és a klinikai döntéshozatalhoz szükséges küszöbértékek meghatározása. Orv. Hetil., 2014, 155(22), 851–857.
Crawley, J. T., Zanardelli, S., Chion, C. K., et al.: The central role of thrombin in hemostasis. J. Thromb. Haemost., 2007, 5(Suppl. 1), 95–101.
Mosesson, M. W.: Fibrinogen and fibrin structure and functions. J. Thromb. Haemost., 2005, 3(8), 1894–1904.
Mann, K. G.: Thrombin formation. Chest, 2003, 124(3 Suppl.), 4S–10S.
Esmon, C. T.: Molecular events that control the protein C anticoagulant pathway. Thromb. Haemost., 1993, 70(1), 29–35.
Coughlin, S. R.: Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost., 2005, 3(8), 1800–1814.
Ten Cate, H.: Thrombin generation in clinical conditions. Thromb. Res., 2012, 129(3), 367–370.
Bauer, K. A.: Activation markers of coagulation. Baillieres Best Pract. Res. Clin. Haematol., 1999, 12(3), 387–406.
Biggs, R., Macfarlane, R. G.: Human blood coagulation and its disorders. Blackwell, Oxford, 1953.
Berntorp, E., Salvagno, G. L.: Standardization and clinical utility of thrombin-generation assays. Semin. Thromb. Hemost., 2008, 34(7), 670–682.
Loeffen, R., Kleinegris, M. C., Loubele, S. T., et al.: Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method. J. Thromb. Haemost., 2012, 10(12), 2544–2554.
Béguin, S., Lindhout, T., Hemker, H. C.: The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb. Haemost., 1989, 61(1), 25–29.
Luddington, R., Baglin, T.: Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J. Thromb. Haemost., 2004, 2(11), 1954–1959.
De Smedt, E., Hemker, H. C.: Thrombin generation is extremely sensitive to preheating conditions. J. Thromb. Haemost., 2011, 9(1), 233–234.
Hemker, H. C., Wielders, S., Kessels, H., et al.: Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb. Haemost., 1993, 70(4), 617–624.
Hemker, H. C., Giesen, P. L., Ramjee, M., et al: The thrombogram: Monitoring thrombin generation in platelet rich plasma. Thromb. Haemost., 2000, 83(4), 589–591.
Ninivaggi, M., Apitz-Castro, R., Dargaud, Y., et al.: Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. Clin. Chem., 2012, 58(8), 1252–1259.
Dargaud, Y., Luddington, R., Gray, E., et al.: Standardisation of thrombin generation test – which reference plasma for TGT? An international multicentre study. Thromb. Res., 2010, 125(4), 353–356.
Hron, G., Kollars, M., Binder, B. R., et al.: Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA, 2006, 296(4), 397–402.
Eichinger, S., Hron, G., Kollars, M., et al.: Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin. Chem., 2008, 54(12), 2042–2048.
Tripodi, A., Legnani, C., Chantarangkul, V., et al.: High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J. Thromb. Haemost., 2008, 6(8), 1327–1333.
Tripodi, A., Legnani, C., Lemma, L., et al.: Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. J. Thromb. Thrombolysis, 2010, 30(2), 215–219.
Van Hylckama Vlieg, A., Christiansen, S. C., Luddington, R., et al.: Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Brit. J. Haematol., 2007, 138(6), 769–774.
Ferroni, P., Martini, F., Portarena, I., et al.: An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients. Thromb. Haemost., 2011, 105(5), 931–932.
Ferroni, P., Martini, F., Portarena, I., et al.: Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients – a pilot study. Support Care Cancer, 2012, 20(11), 2713–2720.
Marchetti, M., Castoldi, E., Spronk, H. M., et al.: Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood, 2008, 112(10), 4061–4068.
Panova-Noeva, M., Marchetti, M., Spronk, H. M., et al.: Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. Am. J. Hematol., 2011, 86(4), 337–342.
Trappenburg, M. C., van Schilfgaarde, M., Marchetti, M., et al.: Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica, 2009, 94(7), 911–918.
Brocal, I., Marco, P., Lucas, J., et al.: Thrombin generation test in patients under anticoagulant therapy with vitamin K antagonists. Thromb. Haemost., 2009, 101(3), 594–595.
Altman, R., Scazziota, A., Herrera, L., et al.: Relationship between thrombin generation and international normalized ratio in patients receiving oral vitamin K antagonist therapy. J. Thromb. Haemost., 2007, 5(7), 1552–1569.
Gerotziafas, G. T., Dupont, C., Spyropoulos, A. C., et al.: Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin. Thromb. Haemost., 2009, 102(1), 42–48.
Al Dieri, R., Alban, S., Béguin, S., et al.: Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J. Thromb. Haemost., 2004, 2(8), 1395–1401.
Gouya, G., Palkovits, S., Kapiotis, S., et al.: Bioactivity of enoxaparin in critically ill patients with normal renal function. Br. J. Clin. Pharmacol., 2012, 74(5), 806–814.
Gatt, A., van Veen, J. J., Woolley, A. M., et al.: Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb. Haemost., 2008, 100(2), 350–355.
Keltai, M., Keltai, K.: New anticoagulants in the prevention and treatment of venous thromboembolism. [Új antikoagulánsok a vénás thromboembolia megelőzésében.] Orv. Hetil., 2011, 152(25), 983–992. [Hungarian]
Graff, J., von Hentig, N., Misselwitz, F., et al.: Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J. Clin. Pharmacol., 2007, 47(11), 1398–1407.
Wong, P. C., White, A., Luettgen, J.: Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. Hosp. Pract., 2013, 41(1), 19–25.
Borissoff, J. I., Joosen, I. A. P. G., Versteylen, M. O., et al: Enhanced endogenous thrombin potential is associated with the severity of coronary atherosclerosis. J. Thromb. Haemost., 2011, 9(Suppl. 2), 746.
Carcaillon, L., Alhenc-Gelas, M., Bejot, Y., et al.: Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly. The three-city cohort study. Arterioscler. Thromb. Vasc. Biol., 2011, 31(6), 1445–1451.
Faber, C. G., Lodder, J., Kessels, F., et al.: Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients. Pathophysiol. Haemost. Thromb., 2003, 33(1), 52–58.
Peyvandi, F., Mannucci, P. M.: Rare coagulation disorders. Thromb. Haemost., 1999, 82(4), 1207–1214.
Van den Berg, H. M., De Groot, P. H., Fischer, K.: Phenotypic heterogeneity in severe hemophilia. J. Thromb. Haemost., 2007, 5(Suppl. 1), 151–156.
Duchemin, J., Pan-Petesch, B., Arnaud, B., et al.: Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb. Haemost., 2008, 99(4), 767–773.
Shima, M., Matsumoto, T., Ogiwara, K.: New assays for monitoring haemophilia treatment. Haemophilia, 2008, 14(Suppl. 3), 83–92.
Keularts, I. M., Hamulyak, K., Hemker, H. C., et al.: The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients. Thromb. Haemost., 2000, 84(4), 638–642.
Váradi, K., Negrier, C., Berntorp, E., et al.: Monitoring the bioavailability of FEIBA with a thrombin generation assay. J. Thromb. Haemost., 2003, 1(11), 2374–2380.
Schols, S. E., Lancé, M. D., Feijge, M. A., et al.: Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. Thromb. Haemost., 2010, 103(2), 318–328.